Management of Metastatic Urothelial Carcinoma in Emerging Markets (EM): An Expert Opinion.
Journal
Clinical genitourinary cancer
Journal Volume
22
Journal Issue
2
Start Page
467
End Page
475
ISSN
1938-0682
Date Issued
2024-04
Author(s)
Soares, Andrey
Bourlon, Maria T
Wong, Alvin
Joshi, Amit
Jardim, Denis
Korbenfeld, Ernesto
Karak, Fadi El
Orlandi, Francisco
Sze, Henry
Ansari, Jawaher
Zarba, Jose
Mansour, Mubarak Al
Manneh, Ray
Thirumulai, Raja
Morsi, Waleed Al
Powles, Thomas
Abstract
Urothelial carcinoma (UC) is the 10 most common cancer globally with an almost 4 times higher prevalence in men. The main risk factors for development of urothelial carcinoma are advanced age, smoking, arsenic contamination, exposure to carcinogens. Metastatic urothelial carcinoma (mUC) has overall poor prognosis with a 5-year overall survival rate of only < 5%. The standard of care comprises of platinum-based chemotherapy, but the responses are often not sustained. A working group was established with an objective to discuss the most recent clinical data on the genitourinary tumors of interest and comprised of experts across Latin America, Emerging Asia (except China, Japan, and South Korea), Africa, and the Middle East (known as Emerging Markets or EM). There is an evident disparity in terms of uneven mortality and incidence rate distribution among various regions. There is a lack and/or insufficient data on epidemiology, treatment, and outcomes in the EM. The lack of registries impacts the healthcare decisions and the lower incidence from the region might not be reflective of the true disease burden. The treatment outcomes of mUC can be improved by understanding the current disease burden and treatment approach of mUC and identifying the gaps and challenges associated with management. Hence, a literature review was developed to summarize the current disease burden and treatment approach of mUC across EM. The review also highlights the unmet needs for mUC management in EM and suggests a way forward to improve the current situation in order to better serve the patients.
Subjects
Bladder cancer
Burden of disease
Emerging Markets
Metastatic urothelial carcinoma
Unmet needs
SDGs
Type
journal article